Novartis' Sandoz aims for 5 biosim launches by 2020

Novartis

Novartis’ Sandoz may only have one biosimilar on the U.S. market right now. But come 2020, that number will be up to 5 between the U.S. and other "key geographies," it says.

The generics giant ($NVS) is aiming to have 11 biosimilar regulatory filings in the can by the end of next year--and it expects those to result in thumbs ups for copies of megablockbusters Enbrel from Amgen and Pfizer, Humira from AbbVie, Neulasta from Amgen ($AMGN), Remicade from Johnson & Johnson ($JNJ) and Merck ($MRK), and Rituxan from Roche ($RHHBY), it said in a Monday statement.

While it’s an ambitious goal--especially considering the U.S. market currently boasts just one biosimilar med--6 of those 11 filings are already on the books, Sandoz said. Most recently, European regulators accepted an application for a copy of cancer star Rituxan.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

And the way the company sees it, if anyone can pull it off, Novartis is the one. It launched the world’s first biosimilar back in 2006--Omnitrope, a recombinant human growth hormone preparation--and last year it rolled out Zarxio, the first to hit the scene in the U.S.

Sandoz isn’t going to get there without some increased spending, though, and plans for that are in the works as well. It intends to sock a combined $1 billion this decade into expanding its manufacturing facilities in Austria, it said.

If Sandoz can get there, the payoff should be hefty. The reference products for the 5 approved biosimilars it sees in its 2020 portfolio generated nearly $44 billion in 2015 global sales.

But it’s not going to happen without some serious IP squabbling. AbbVie, for one, has told its investors multiple times that it has a “robust” patent defense system in place on Humira, the world’s best-selling med.

- read Sandoz' release

Special Report: The top 20 generics companies by 2014 revenue - Novartis - Sandoz

Related Articles:
Novartis targets Amgen's Enbrel with second biosimilar app
'Cornerstone' patent on AbbVie's Humira comes under PTAB review
Novartis takes aim at Remicade market with EU biosim rights from Pfizer
Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do?
Amgen's Neupogen won't face Novartis biosim till September: court

Read more on

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

Kinase inhibitors to treat cancer have driven nearly $100 billion in deals since 2010, a trend that's likely to grow, SVB Leerink analysts predict.